Navigation Links
Dendreon Reports Third Quarter 2010 Financial Results
Date:11/3/2010

SEATTLE, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2010. Revenue for the third quarter ended September 30, 2010 was $20.2 million compared to $25,000 for the quarter ended September 30, 2009. Revenue for the nine months ended September 30, 2010 was $23.1 million compared to $80,000 for the nine months ended September 30, 2009.  

Revenue from sales of PROVENGE® (sipuleucel-T) steadily increased month over month from $5.2 million in July, to $7.2 million in August and $7.8 million in September. In addition, revenue for October was approximately $9.5 million.

“We’re pleased with the progress we have made in the first six months of the launch of PROVENGE,” said Mitchell H. Gold, M.D., president and chief executive officer. “We look forward to making PROVENGE available to the many patients who may benefit from it and who have had very few appealing treatment options prior to the FDA approval of PROVENGE.”

Dendreon's total operating expenses for the third quarter of 2010 were $87.7 million compared to $25.8 million in the third quarter of 2009. Dendreon’s total operating expenses for the nine months ended September 30, 2010 were $213.7 million compared to $63.7 million for the same period in 2009. Total operating expenses for the three and nine months ended September 30, 2010 include a charge of $13.3 million for the settlement of litigation. The net loss for the quarter ended September 30, 2010 was $79.3 million, or $0.56 per share, which includes a $0.09 charge for the litigation settlement, compared to $45.6 million, or $0.40 per share for the quarter ended September 30, 2009, which included a non-cash charge associated with the revaluation of warrants of $19.4 million or $0.17 per share. The net loss for the nine months ended S
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
2. Dendreon Statement on CMS National Coverage Analysis
3. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
4. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
5. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
6. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
7. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
8. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
... Aug. 23 /PRNewswire-FirstCall/ -- Today at ... FUJIFILM Medical Systems U.S.A., Inc. announced that it ... D-EVO™ flat panel detector.  As U.S. installations of ... departments will begin benefiting from the seamless transition ...
... today announced that it has signed an exclusive agreement ... tablets) 10 mcg.  Under the terms of the agreement, ... in the U.S. beginning August 2 through the company,s ... Vagifem® 10 mcg to the U.S. market earlier this ...
Cached Medicine Technology:FUJIFILM's FDR D-EVO™ is Now Available and Shipping 2Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg 2Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg 3
(Date:9/30/2014)... Somerset, N.J. (PRWEB) September 30, 2014 ... global provider of advanced delivery technologies and development ... today announced a full agenda for the 25th ... Paris, France, from October 6th to 9th. , ... and supply capability expansions during the show, including ...
(Date:9/30/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on 5 reasons why relapse shouldn’t stand in the way ... a one-time event, like reaching the finish line of a ... “It’s an ongoing process and a lifelong commitment that will ...
(Date:9/30/2014)... devised a way to rapidly test hundreds of different ... discover promising new ways to deliver a class of ... DNA, to human patients. , In a study appearing ... used this technology to identify materials that can efficiently ... type of high-speed screen could help overcome one of ...
(Date:9/30/2014)... cells cannot multiply and cardiac muscles contain few ... itself after a heart attack. Now Tel Aviv ... standard in cardiac tissue engineering. , Dr. Tal ... TAU,s Department of Biotechnology, Department of Materials Science ... have been developing sophisticated micro- and nanotechnological tools ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 RISC ... IT Infrastructure analytics across data center, cloud and ... achieved an important milestone of helping more than ... for important projects such as IT infrastructure transformation, ... , The strong customer engagement rates and partner ...
Breaking Medicine News(10 mins):Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:New Best Drug Rehabilitation Blog Post Focuses on 5 Reasons Why Relapse Shouldn’t Stand in the Way of Recovery 2Health News:New Best Drug Rehabilitation Blog Post Focuses on 5 Reasons Why Relapse Shouldn’t Stand in the Way of Recovery 3Health News:High-speed drug screen 2Health News:High-speed drug screen 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3
... methodology behind WHO rankings, WASHINGTON, Feb. 26 ... in what could be,the final debate before the nominee ... be a topic of discussion. But as the two ... tales of people (invariably,swing state residents) encountered on the ...
... YORK (Feb. 26, 2008) -- As many as ... not respond to the standard first-line chemotherapy placed ... data. When this happens, typically, their only option ... at the Herbert Irving Comprehensive Cancer Center of ...
... Feb. 26 ULLICO Casualty Group (ULLICO,Casualty) has ... fiduciary and union liability insurance programs. Hudson is ... than $2,billion) by A.M. Best Company. Hudson is ... the holding company for one of the world,s,largest ...
... provoked soil-dwelling bacteria into producing a new type of ... in a battle for survival. , The antibiotic holds ... ulcers in humans. Also, figuring out the still murky ... help scientists develop strategies for finding other new antibiotics. ...
... Board: HFIT), a leading employee health improvement company,will report ... 31, 2007, on Wednesday, March 5, 2008, after the ... a conference call to discuss the,results the same day. ... and chief executive officer, and Wes Winnekins, chief financial,officer., ...
... 26 At Beverly Hills,Liposculpture, Dr. Alan Bittner ... safe breast reduction surgery that can reduce,breasts by ... The procedure,called liposculpture breast reduction, takes approximately 90 ... fat (more than 3 coke cans!) from each ...
Cached Medicine News:Health News:World Health Report Rankings Driven by Ideology, Skewed Data 2Health News:Study looks at new bladder cancer therapy for patients unresponsive to standard treatment 2Health News:ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance 2Health News:ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance 3Health News:Bacterial 'battle for survival' leads to new antibiotic 2Health News:Bacterial 'battle for survival' leads to new antibiotic 3Health News:Health Fitness Corp. to Report Fourth Quarter and Year End 2007 Financial Results on March 5, 2008 2Health News:Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50% 2Health News:Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50% 3
Inquire...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
Medicine Products: